Trial · NCT04742504
Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
NCT04742504, Completed, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Interaction Between Benralizumab and Basophils in Eosinophilic Asthma. Trials, record NCT04742504. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04742504
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
- NCT number
- NCT04742504
- Status
- Completed
- Enrollment
- 20 participants, actual
- Lead sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Conditions
- Asthma; Eosinophilic
- Interventions
- BENRALIZUMAB
- First posted
- 2021-02-08
- Last updated
- 2023-10-17
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fold changes in number of basophils | From 1 to 12 months | Fold changes in number of basophils after 8 week, 6 months and 1 year of benralizumab treatment (Fasenra®, Astra Zeneca) in blood and sputum in patients with severe eosinophilic asthma |
| Primary | Fold changes in number of innate inmmune cells | From 1 to 12 months | Fold changes in number of innate immune cells s after 8 week, 6 months and 1 year of benralizumab treatment (Fasenra®, Astra Zeneca) in blood and sputum in patients with severe eosinophilic asthma |
| Primary | The fold changes of IL-5R expression in basophils | From 1 to 12 months | The fold changes of IL-5R expression in basophils after 8 week, 6 months and 1 year of benralizumab treatmen |
| Primary | The fold changes of f IL-5R expression in innate lymphoid cells | From 1 to 12 months | The fold changes of f IL-5R expression in innate lymphoid cells after 8 week, 6 months and 1 year of benralizumab treatment |
| Secondary | Fold changes of miRNAs profile in basophils | From 6 to 18 | 1\. Fold changes of miRNAs profile in basophils after tratment of Benralizumab in in patients with severe eosinophilic asthma treatment. |
| Secondary | Fold changes of serum IL-5R | Fromm 6 to 12 | Fold changes of serum IL-5R (microg/ml) in patients treated with benralizumab |
| Secondary | Effect of benralizumab in basophil apoptosis | From 12 to 24 months | The effect of benralizumab in basophil apoptosis isolated from from allergic asthmatic patients will be measure by fold change of annexin V |
| Secondary | Effect of benralizumab in KU812 apoptosis | From 12 to 24 months | The effect of benralizumab in KU812 apoptosis will be measure by fold change of annexin V in KU812 cultures |
| Secondary | Effect of benralizumab in basophil activation | From 12 to 24 months | The effect of benralizumab in basophil activation isolated from from allergic asthmatic patients will be measur by fold change of CD63, and CD203C on membrane by flow cytometry |
| Secondary | Effect of benralizumab in KU812 activation | From 12 to 24 months | The effect of benralizumab in KU812 activation will be measurie by fold change of CD63, and CD203C on membrane by flow cytometry |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04742504
GET https://conductscience.org/api/trials/v1/NCT04742504/registered